EMEA-001526-PIP01-13-M05
Table of contents
Key facts
| Invented name |
Natpar
|
| Active substance |
Recombinant parathyroid hormone
|
| Therapeutic area |
Endocrinology-Gynaecology-Fertility-Metabolism
|
| Decision number |
P/0369/2021
|
| PIP number |
EMEA-001526-PIP01-13-M05
|
| Pharmaceutical form(s) |
Powder and solvent for solution for injection
|
| Condition(s) / indication(s) |
Treatment of hypoparathyroidism
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Takeda Pharmaceuticals International AG Ireland Branch
E-mail: medinfoEMEA@takeda.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|